# SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

> **NCT06401005** · PHASE2 · RECRUITING · sponsor: **Hubei Cancer Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cadonilimab (AK104)

## Key facts

- **NCT ID:** NCT06401005
- **Lead sponsor:** Hubei Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-28
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-09-01
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401005, "SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06401005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*